You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Calliditas reveals results from vital NefIgArd study

Calliditas Therapeutics has announced publication of its NefIgArd trial inĀ The Lancet. The phase 3 study concerns the use of Nefecon among adult patients with primary IgA nephropathy (IgAN).